Simplex Trading LLC Decreases Holdings in ProShares Ultra Nasdaq Biotechnology ETF (BIB)

Simplex Trading LLC cut its stake in shares of ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) by 74.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,338 shares of the exchange traded fund’s stock after selling 6,811 shares during the period. Simplex Trading LLC’s holdings in ProShares Ultra Nasdaq Biotechnology ETF were worth $131,000 as of its most recent SEC filing.

Shares of ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ BIB) opened at $60.40 on Thursday. ProShares Ultra Nasdaq Biotechnology ETF has a 12 month low of $40.22 and a 12 month high of $64.51.

COPYRIGHT VIOLATION NOTICE: “Simplex Trading LLC Decreases Holdings in ProShares Ultra Nasdaq Biotechnology ETF (BIB)” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://sportsperspectives.com/2018/01/11/simplex-trading-llc-decreases-holdings-in-proshares-ultra-nasdaq-biotechnology-etf-bib.html.

ProShares Ultra Nasdaq Biotechnology ETF Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply